title: Initial Standardized Uptake Value of Positron Emission Tomography Influences the Prognosis of Patients with Localized Gastric Adenocarcinoma Treated Preoperatively.
abstract: BACKGROUND
  In patients with localized gastric adenocarcinoma (LGAC) who receive preoperative therapy, tools to predict response or prognosticate outcome before therapy are lacking. We used initial standardized uptake value (iSUV) of positron emission tomography (PET) to evaluate its association with overall survival (OS).
  
  
  METHODS
  We identified 60 patients with confirmed LGAC who were treated with preoperative chemoradiation and had a baseline PET in addition to other routine staging. Fisher's exact test and Wilcoxon's rank sum test were used to determine the association between iSUV and other variables, and the log-rank test and Cox proportional hazards model were used for survival analysis.
  
  
  RESULTS
  The median iSUV was 6 (range, 0-28). The presence of signet ring cells in pretreatment biopsies correlated highly with low iSUV (≤ 6; p = 0.0017). Patients with a high iSUV (> 6) had a longer OS compared to those with a low iSUV (≤ 6; p = 0.0344). iSUV was not an independent predictor (p = 0.12); however, the risk of death was reduced for patients with an iSUV > 6 (hazard ratio = 0.26).
  
  
  CONCLUSIONS
  Our novel findings show that among LGAC patients treated with preoperative chemoradiation and surgery, those with a high iSUV have longer OS than patients with a low iSUV. iSUV appears to have a predictive role in patients with LGAC when treated with preoperative chemoradiation.
authors.affiliation: Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Tex., USA.
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Charalampakis
authors.forename: Lianchun
authors.initials: L
authors.lastname: Xiao
authors.forename: Elena
authors.initials: E
authors.lastname: Elimova
authors.forename: Roopma
authors.initials: R
authors.lastname: Wadhwa
authors.forename: Hironori
authors.initials: H
authors.lastname: Shiozaki
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Shimodaira
authors.forename: Mariela A
authors.initials: MA
authors.lastname: Blum
authors.forename: Venkatram
authors.initials: V
authors.lastname: Planjery
authors.forename: Jane E
authors.initials: JE
authors.lastname: Rogers
authors.forename: Aurelio
authors.initials: A
authors.lastname: Matamoros
authors.forename: Tara
authors.initials: T
authors.lastname: Sagebiel
authors.forename: Prajnan
authors.initials: P
authors.lastname: Das
authors.forename: Jeffrey H
authors.initials: JH
authors.lastname: Lee
authors.forename: Manoop S
authors.initials: MS
authors.lastname: Bhutani
authors.forename: Brian
authors.initials: B
authors.lastname: Weston
authors.forename: Jeannelyn S
authors.initials: JS
authors.lastname: Estrella
authors.forename: Brian D
authors.initials: BD
authors.lastname: Badgwell
authors.forename: Jaffer A
authors.initials: JA
authors.lastname: Ajani
mesh_terms: D000230:Adenocarcinoma / Q000000981:diagnostic imaging* / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D011300:Preoperative Care; D011379:Prognosis; D011446:Prospective Studies; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D013274:Stomach Neoplasms / Q000000981:diagnostic imaging* / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D015996:Survival Rate; D014018:Tissue Distribution
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18